SIC
RIGL icon

SJS Investment Consulting’s Rigel Pharmaceuticals RIGL Stock Holding History

SJS Investment Consulting’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79 Buy
2
+1
+100% +$31 ﹤0.01% 2653
2026
Q1 		$28 Sell
1
-3
-75% -$101 ﹤0.01% 2340
2025
Q4 		$172 Buy
+4
New +$151 ﹤0.01% 1845

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's RIGL Position: Q2 2026 in Review

SJS Investment Consulting increased its Rigel Pharmaceuticals (RIGL) stake by 100% in Q2 2026, buying an estimated $31 and bringing the position to 2 shares worth $79. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

SJS Investment Consulting first reported a position in RIGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $172 in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • SJS Investment Consulting held 2 shares of Rigel Pharmaceuticals worth $79 as of Q2 2026.
  • SJS Investment Consulting bought 1 Rigel Pharmaceuticals share in Q2 2026, an estimated $31.
  • Rigel Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2653 holding.
  • SJS Investment Consulting first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • SJS Investment Consulting's Rigel Pharmaceuticals position peaked at $172 in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.